GRAL vs TMDX: Which Stock Is the Better Buy?
GRAIL, Inc. and TransMedics Group, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — GRAL vs TMDX, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| GRAIL, Inc. (GRAL) | TransMedics Group, Inc. (TMDX) | |
|---|---|---|
| Market cap | $2.6B | $2.6B |
| Revenue (latest FY) | $147.17M | $605.49M |
| Net income (latest FY) | $-408.35M | $190.29M |
| Revenue growth (5y CAGR) | 38.4% | 88.2% |
| Net margin | -277.5% | 31.4% |
| Return on equity | -15.8% | 40.2% |
| P/E ratio | — | 17.0 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 2 |
| Positive free cash flow | No | Yes |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full GRAL vs TMDX breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open GRAL's full financials → Open TMDX's full financials →More comparisons
Frequently asked questions
Which is bigger, GRAL or TMDX?
GRAIL, Inc. is larger by market capitalization — $2.6B versus $2.6B.
Which grows faster, GRAL or TMDX?
Over the last five fiscal years, TransMedics Group, Inc. grew revenue faster — 88.2%/yr versus 38.4%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.